key: cord-0827250-r1tp27z8
authors: Tande, Aaron J; Pollock, Benjamin D; Shah, Nilay D; Farrugia, Gianrico; Virk, Abinash; Swift, Melanie; Breeher, Laura; Binnicker, Matthew; Berbari, Elie F
title: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
date: 2021-03-10
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab229
sha: dd5309fedd2d04e7aad1493495f479358f478828
doc_id: 827250
cord_uid: r1tp27z8

BACKGROUND: Several vaccines are now clinically available under emergency use authorization in the United States and have demonstrated efficacy against symptomatic COVID-19. The impact of vaccines on asymptomatic SARS-CoV-2 infection is largely unknown. METHODS: We conducted a retrospective cohort study of consecutive, asymptomatic adult patients (n = 39,156) within a large United States healthcare system who underwent 48,333 pre-procedural SARS-CoV-2 molecular screening tests between December 17, 2020 and February 8, 2021. The primary exposure of interest was vaccination with at least one dose of an mRNA COVID-19 vaccine. The primary outcome was relative risk of a positive SARS-CoV-2 molecular test among those asymptomatic persons who had received at least one dose of vaccine, as compared to persons who had not received vaccine during the same time period. Relative risk was adjusted for age, sex, race/ethnicity, patient residence relative to the hospital (local vs. non-local), healthcare system regions, and repeated screenings among patients using mixed effects log-binomial regression. RESULTS: Positive molecular tests in asymptomatic individuals were reported in 42 (1.4%) of 3,006 tests performed on vaccinated patients and 1,436 (3.2%) of 45,327 tests performed on unvaccinated patients (RR=0.44 95% CI: 0.33-0.60; p<.0001). Compared to unvaccinated patients, the risk of asymptomatic SARS-CoV-2 infection was lower among those >10 days after 1 (st) dose (RR=0.21; 95% CI: 0.12-0.37; p<.0001) and >0 days after 2 (nd) dose (RR=0.20; 95% CI: 0.09-0.44; p<.0001) in the adjusted analysis. CONCLUSIONS: COVID-19 vaccination with an mRNA-based vaccine showed a significant association with a reduced risk of asymptomatic SARS-CoV-2 infection as measured during pre-procedural molecular screening. The results of this study demonstrate the impact of the vaccines on reduction in asymptomatic infections supplementing the randomized trial results on symptomatic patients.

Since the beginning of the COVID-19 pandemic, more than two million lives have been lost and the global society has been disrupted in an unprecedented manner [1] . Despite significant efforts leveraging nonpharmacologic interventions such as use of face masks, physical distancing, community stay-at-home measures, quarantine, and isolation, spread has continued throughout much of the world. Ongoing infection and subsequent transmission from asymptomatic individuals is a significant contributing factor to the ongoing pandemic, with more than half of all transmission estimated to occur from individuals without symptoms [2] .

Disrupting the rate of asymptomatic transmission is critical to bringing the pandemic to an end.

Through an unprecedented global effort at vaccine development, several vaccines have been licensed for use across the world. The data supporting the approval of these vaccines were based on reduction of symptomatic or severe COVID-19 disease. Published results from latestage clinical trials show that the vaccine efficacy at preventing symptomatic COVID-19 disease ranged from 70.4-95% [3] [4] [5] . There is significant uncertainty, however, in the impact of COVID-19 vaccination on asymptomatic SARS-CoV-2 infection and transmission risk. The ability of vaccination to reduce asymptomatic or minimally symptomatic infection will be critical to ending the pandemic, given the relative contribution of asymptomatic infection to viral transmission. There are limited real-world data on the impact of vaccination on asymptomatic SARS-CoV-2 infection, which severely limits the development of post-vaccination behavior recommendations and may contribute to vaccine hesitancy [6] . Within our healthcare system, patients are routinely evaluated for symptomatic and asymptomatic SARS-CoV-2 infection prior to surgery and medical procedures, which have A c c e p t e d M a n u s c r i p t 6 potential to generate an aerosol. This approach has been in place since April 2020, in an effort to prevent patient harm from operative complications related to COVID-19 and decrease potential exposure and transmission to healthcare personnel [7] . Preoperative evaluation has included patient symptom questionnaires before and upon arrival at our medical facilities, combined with SARS-CoV-2 molecular testing performed just prior to selected medical and surgical procedures.

In this study, we sought to evaluate the real-world impact of vaccination on pre-procedural SARS-CoV-2 molecular test positivity among individuals without symptoms and to assess the impact of vaccination on asymptomatic/pre-symptomatic infection.

This was a retrospective cohort study that included all consecutive molecular screening tests performed in adult (≥18 years old) patients at Mayo Clinic campuses located in Rochester, MN, Phoenix, AZ, and the Mayo Clinic Health System (located in Minnesota and Wisconsin) who underwent pre-procedural and pre-surgical SARS-CoV-2 molecular testing (henceforth referred to as pre-procedural molecular screening) within 48-72 hours of their procedure. All patients undergoing testing between December 17, 2020 to February 8, 2021 were included.

December 17, 2020 was chosen as this was the first date that vaccines were administered at these sites. In the Midwest region (Rochester, MN campus and the Mayo Clinic Health System), criteria for pre-procedural molecular screening was determined by a multidisciplinary COVID-19 Diagnostic Stewardship Committee, with ongoing review on a weekly basis [8] . The Arizona campus uses similar guidance to determine the need for pre-procedural molecular screening. In general, all surgical procedures requiring general anesthesia and other select medical procedures (Supplemental material) required pre-procedural molecular screening. In addition to molecular A c c e p t e d M a n u s c r i p t 7 screening, patients were asked whether they had fever or other COVID-19 symptoms that were new or not related to a pre-existing condition prior to their surgical procedure through a standardized phone or electronic questionnaire (Supplemental material), as well as when arriving onsite for their procedure. Patients were not followed to assess for development of subsequent symptoms. Patients tested due to symptoms or a known exposure were tested using an alternative ordering process and were excluded from this analysis. This study was deemed exempt by the Mayo Clinic IRB.

For this study, all patient-level data from molecular screening tests (including test collection date/time, and Mayo Clinic site), vaccinations (including vaccination manufacturer, date/time, dose, Mayo Clinic site) and patient demographic data (age, sex, race/ethnicity, state of residence) were captured in the electronic health record (EHR) and compiled in an institutionally-curated COVID-19 database housing distinct tables for molecular testing, serology testing, and inpatient COVID-19 data. This database represents the primary, centralized source of COVID-19 data at our institution and is easily accessible through Structured Querying Language (SQL) [9] .

The primary exposure was vaccination with at least one dose of the BNT162b2 (Pfizer, Inc., New York, NY) or mRNA-1273 (Moderna, Inc., Cambridge, MA) SARS-CoV-2 vaccines prior to molecular screening. We assessed exposure as vaccinated (with any number of doses and at any time interval) prior to SARS-CoV-2 molecular screening versus unvaccinated prior to A c c e p t e d M a n u s c r i p t 8 screening. We also conducted analyses categorizing patients by timing of vaccination (days from vaccination to screening) as well as by number of doses (0, 1, or 2) prior to screening. We further conducted a subgroup analysis for those receiving the Pfizer vaccine.

The outcome was relative risk of a positive test at pre-procedural molecular screening.

The period prevalence, more commonly termed percent positivity, was also determined and aggregated by exposure categories. Molecular testing was performed through a combination of emergency use authorized methods depending on the Mayo Clinic location, including a SARS-CoV-2 laboratory-developed real-time PCR [10] , the APTIMA SARS-CoV-2 transcriptionmediated amplification assay (Hologic, Marlborough, MA), and the Abbott RealTime SARS-CoV-2 real-time PCR method [11] . When available, we obtained the cycle threshold (Ct) or 

Patient demographics including age, sex, race/ethnicity, county and state of residence, and whether the patient resided in the hospital's Health Referral Region (HRR), a proxy for whether or not that patient was 'local', were gathered and compared between those who were vaccinated prior to molecular screening versus those who were unvaccinated at the time of screening using a chi-squared test for sex and state of residence and a t-test for age. We calculated the percent positivity of molecular screening comparing vaccinated and unvaccinated A c c e p t e d M a n u s c r i p t 9 groups and compared these using log-binomial regression to estimate the unadjusted Relative Risk (RR) and 95% CI.

For patients vaccinated prior to molecular screening, we calculated 'days-to-screening' by subtracting the date of molecular screening from the date of vaccination and plotted Kaplan-Meier survival analysis by number of doses received. Rarely, patients were vaccinated on the same day as their pre-procedure molecular screening. For these patients (n = 151), we considered them to be 'vaccinated' prior to screening and calculated the days-to-screening as zero. We categorized timing as: unvaccinated prior to screening; screening 0-10 days after 1 st dose; screening >10 days after 1 st dose; screening >0 days after 2 nd dose. Finally, we analyzed data based on the number of doses prior to screening. Patients were categorized as having received 0 doses (unvaccinated), 1 dose, or 2 doses. The percent positivity and exact 95% confidence intervals (CI) for these four vaccination groups were calculated and analyzed as described above. We also conducted sub-group analysis by assessing the timing categories described above within patients who received only the BNT162b2 (Pfizer) vaccine. There were not a sufficient number of patients receiving the mRNA-1273 (Moderna) vaccine to perform a sub-group analysis for that group. All analyses were repeated with adjustment in mixed effect models with random intercepts for each Mayo Clinic site (Rochester, MCHS, and Arizona), a random residual to correct for intra-patient repeated measures, and fixed effects for age, sex, race/ethnicity, and patient residence relative to the hospital (local vs. non-local).

There were 48,333 molecular screening tests performed among 39,156 unique patients during the study period. Mean (SD) age was 54.2 (19.7) years and 25,364 (52.5%) were female. There were 3,006 (6.2%) screening tests performed on individuals who were vaccinated prior to their A c c e p t e d M a n u s c r i p t 10 molecular screening ( Table 1) . Those who were vaccinated were significantly younger and more likely to be female than those without prior vaccination reflecting the early focus on vaccinating health care workers. We observed differences in the race, state of residence and residence within the local HRR. Among the vaccinated group, median (IQR) time from first dose of vaccine to their molecular screening was 16 days (7 days Table S1 and Table S2 ). Multiple different testing methods were used in these patients, limiting the comparison between vaccinated and unvaccinated groups to only those tested using the same method. Interestingly, the Ct values of positive results from vaccinated individuals at our Arizona location were significantly lower (p < 0.01) than for unvaccinated individuals, but there were no other significant differences. Among positive tests in Arizona, there was a non-significant difference in the Ct value when analyzed by timing after vaccination (Supplemental Material, Table S2 ).

In this real-world study, we observed that vaccination using an mRNA COVID-19 vaccine is associated with a reduced rate of asymptomatic SARS-CoV-2 infection among individuals tested during pre-procedural molecular screening. We observed a significant decrease in asymptomatic infection, consistent in timing and magnitude with what has been observed in clinical trials evaluating the prevention of symptomatic infection after vaccination with mRNA vaccine [3, 4] . Among individuals who had received a single dose of vaccine >10 days prior to their pre-procedure test, we observed a 72% reduction in the risk of a positive molecular screening test. When analysis was limited to those individuals who received two Compared to the clinical trial efficacy results reported for the BNT162b2 and mRNA-1273 vaccines [3, 5] , this reduction in efficacy is not unexpected, given that 36% of post-second dose tests were performed fewer than seven days after their second dose of vaccine. The impact of vaccine on asymptomatic SARS-CoV-2 infection is likely to be dependent on the efficacy of the specific vaccine. As an example, a single standard dose of the ChAdOx1 nCoV-19 vaccine (Astra Zeneca) did not provide consistent protection against asymptomatic infection [12] . In an analysis performed from 22-90 days after the first vaccine dose, there was no protection against asymptomatic infection. However, among individuals who received two doses of vaccine 12 or more weeks apart, there was a 47% reduction in asymptomatic infection when measured ≥14 days after the second dose. Reduction in asymptomatic infection is also likely impacted by timing of vaccine doses. Analyses similar to the one conducted in our study will be needed to better understand the real-world impact for other vaccines as they receive authorization in the US.

There are several limitations to this study. First, there may have been unmeasured confounding factors that contributed to the lower rate of molecular test positivity within the group that received vaccination. Accordingly, one can only infer correlation between vaccination and reduced molecular test positivity, rather than causation. For most of the observation period, vaccine availability was limited to healthcare personnel and residents of long-term care facilities, due to the increased risk for COVID-19 exposure in these populations.

However, one would not be surprised to find higher rates of test positivity in preprocedural screening of these groups; the fact that lower positivity rates were seen in the vaccinated cohort supports a significant mitigating effect of vaccination. We attempted to adjust for confounding factors through an adjusted analysis and observed that the strength of association between vaccine receipt and a decline in test positivity only strengthened. Nevertheless, it is possible that unmeasured confounders remain and contributed to our observations. This study was performed in a largely White, non-Hispanic population that was under the age of 65. A second limitation is A c c e p t e d M a n u s c r i p t 14 that patients undergoing pre-procedural molecular screening may have been symptomatic or in the pre-symptomatic phase of COVID-19 infection. We relied upon our existing clinical mechanisms to exclude tests ordered on symptomatic patients from this analysis. Some individuals may have not responded to the pre-visit phone call or electronic questionnaire or the personnel asking the questions may not have asked all of the questions. Patients may have not been truthful in their responses. We did not longitudinally follow these patients to assess for development of subsequent symptoms. Therefore, our results may reflect a combination of asymptomatic and mildly symptomatic cases. We attempted to address this limitation by only including patients who underwent testing ordered via an order panel performed for pre-procedure molecular testing, as well as through the existing pre-procedure symptom questionnaire process to identify patients who were symptomatic. Patients who were identified as symptomatic on questionnaire would have been tested through a separate process and excluded from this analysis. In summary, previous receipt of an mRNA COVID-19 vaccine was associated with an 80% reduction of risk in asymptomatic COVID-19 in patients that have received 2 vaccines when compared to those who had not been vaccinated. These results are consistent with previously published data showing a reduction in asymptomatic infection following vaccination with an mRNA vaccine, even after one dose [3] . From a public health perspective, it will be important to determine if the current recommendations to maintain pre-vaccination behaviors for masking and social distancing will impact vaccine hesitancy. These data together with further studies will inform on the risk benefit balance of current post vaccination guidelines. 

COVID-19) Dashboard. World Health Organization

SARS-CoV-2 Transmission From People Without COVID-19 Symptoms

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet

Post-Vaccination COVID-19 among Healthcare Workers

Revamping Outpatient Care for Patients Without COVID-19

Diagnostic Stewardship: An Essential Element in a Rapidly Evolving COVID-19 Pandemic

Deployment of an Interdisciplinary Predictive Analytics Task Force to Inform Hospital Operational Decision-Making During the COVID-19 Pandemic

Evaluation of Saline, Phosphate-Buffered Saline, and Minimum Essential Medium as Potential Alternatives to Viral Transport Media for SARS-CoV-2 Testing

Low Utility of Repeat Real-Time PCR Testing for SARS-CoV-2 in Clinical Specimens

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Race White, non-Hispanic African or African-American Asian or Asian-American Hispanic of any race Other/Unknown

A c c e p t e d M a n u s c r i p t 17 A c c e p t e d M a n u s c r i p t